eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2019
vol. 36
 
Share:
Share:
abstract:
Review paper

Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors

Grażyna Kamińska-Winciorek
1
,
Bożena Cybulska-Stopa
2
,
Iwona Ługowska
3, 4, 5
,
Marek Ziobro
2
,
Piotr Rutkowski
3

  1. Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sk³odowska-Curie Institute – Oncology Center, Gliwice Branch, Gliwice, Poland
  2. Maria Sk³odowska-Curie Institute – Oncology Center, Krakow Branch, Krakow, Poland
  3. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sk³odowska-Curie Institute – Oncology Center, Warsaw, Poland
  4. Department of Epidemiology and Biostatistics, Mother and Child Institute, Warsaw, Poland
  5. Early Phase Clinical Trials Unit, Warsaw, Maria Sk³odowska-Curie Institute – Oncology Center, Warsaw, Poland
Adv Dermatol Allergol 2019; XXXVI (4): 382-391
Online publish date: 2019/08/30
View full text Get citation
 
The introduction of immunotherapy into the treatment of cancer patients has revolutionised the oncological approach and significantly improved patient survival. The key drugs are immune checkpoint inhibitors (CPIs), whose mechanism of action is to elicit immune response against cancer cell antigens. Three types of CPIs are currently used and approved: an anti-CTLA-4 antibody, ipilimumab; anti-PD-1 antibodies, nivolumab and pembrolizumab; and anti-PD-L1 antibodies: atezolizumab, avelumab and durvalumab. CPIs have been widely used in metastatic and adjuvant melanoma settings, metastatic lung cancer, Hodgkin’s lymphoma, renal cancer, bladder cancer, head and neck tumours, and Merkel cell carcinoma. However, side effects of CPIs differ from toxicities of other oncological drugs. According to literature data, in 10–30% of patients CPIs are responsible for immune-related adverse events (irAE) associated with excessive activation of the immune system. Systemic irAEs include enterocolitis, pneumonitis, hepatitis, nephritis, hypophysitis, and autoimmune thyroid disease. However, the most common irAEs of checkpoint inhibitors are dermatologic toxicities ranging from pruritus and mild dermatoses to severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. Each irAE can become serious if not early diagnosed and appropriately treated. In the article we present different types of skin irAEs related to CPIs together with the recommended therapies.
keywords:

skin toxicities, immune checkpoint antibody

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.